<ul>
<li>Sino Biopharmaceutical disclosed Phase I results for Kylo-0603, a liver-targeted THR-β agonist, presented at the EASL 2026 Congress.     *      The first-in-human study in healthy volunteers showed the oral drug was generally well tolerated, with no serious safety signals reported.     *      Participants receiving Kylo-0603 showed improved lipid profiles versus placebo, supporting its metabolic liver disease rationale.     *      The program targets MAFLD and MASH, positioning Kylo-0603 as a potential oral option with reduced off-target thyroid effects.     *      A Phase II trial is planned to start within 2026, setting up the next value inflection point for the asset. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260527-12172424), on May 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</li>
</ul>

01177

<p>Sino Biopharmaceutical presented Phase I results for Kylo-0603, a THR-β agonist, at EASL 2026. The study showed the drug was well tolerated with no serious safety issues, and improved lipid profiles in participants. Targeting MAFLD and MASH, Kylo-0603 may offer a safer oral option. A Phase II trial is set to begin in 2026.</p>

Sino Biopharma presents Phase I data for Kylo-0603 THR-β agonist at EASL 2026